Aileron Therapeutics is an American biopharmaceutical company based in Cambridge, Massachusetts.
Organization
| Name | Position | Notes |
|---|---|---|
| Loren Walensky | Scientific Advisory Board member and consultant[1] | Rochelle Walensky, Dana-Farber Cancer Institute, Lytica Therapeutics |
Investors
Investors in Aileron Therapeutics include:[2][3][4][5]
- Acorn Bioventures
- Aju IB Investment
- Apple Tree Partners
- BVF Partners
- CB Health Ventures
- Eli Lilly
- Excel Venture Management
- Grand Oaks Capital
- Lincoln Park Capital Fund
- Maven Investment Partners
- Novartis Venture Fund (NVF)
- Roche
- Satter Investment Management
- SR One
External links
Mourtada, R., Herce, H. D., Yin, D. J., Moroco, J. A., Wales, T. E., Engen, J. R., & Walensky, L. D. (2019). Design of stapled antimicrobial peptides that are stable, nontoxic and kill antibiotic-resistant bacteria in mice. Nature Biotechnology, 37(10), 1186–1197. https://doi.org/10.1038/s41587-019-0222-z ↩︎
Aileron Therapeutics - Funding, Financials, Valuation & Investors. Crunchbase. Retrieved May 11, 2023, from https://www.crunchbase.com/organization/aileron-therapeutics/company_financials ↩︎
Series A - Aileron Therapeutics - 2006-12-01 - Crunchbase Funding Round Profile. Crunchbase. Retrieved May 11, 2023, from https://www.crunchbase.com/funding_round/aileron-therapeutics-series-a--f1823f7a ↩︎
Series D - Aileron Therapeutics - 2009-06-11 - Crunchbase Funding Round Profile. Crunchbase. Retrieved May 11, 2023, from https://www.crunchbase.com/funding_round/aileron-therapeutics-series-d--7c3c2e71 ↩︎
Series E - Aileron Therapeutics - 2014-10-29 - Crunchbase Funding Round Profile. Crunchbase. Retrieved May 11, 2023, from https://www.crunchbase.com/funding_round/aileron-therapeutics-series-e--740ce9be ↩︎
